NEW YORK (GenomeWeb News) - Proteomics company CS-Keys said yesterday that it has received a "significant" but undisclosed seed investment from Midwest VC firm Triathlon Medical Ventures.
CS-Keys, based in Indianapolis, will use the investment to continue researching and developing its cancer-specific biomarkers and supporting its marketing and regulatory strategies.
Earlier this year, CS-Keys received a $285,000 investment from the BioCrossroads-managed Indiana Seed Fund. Triathlon is part of the Indiana Future Fund, a $73-million fund-of-funds organized through BioCrossroads and focused on early-stage Indiana life sciences investments.
CS-Keys was formed in February 2005 and is using proteomics techniques to create biomarkers for identifying malignant cells.